Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7562351-lung-care-asthma-mobile-app/
Mehta Eye Clinic, a leading Eye care specialty clinic in Ghatkopar, Mumbai, has always been on the forefront of technology. With an aspiration to bring the latest and most advanced Eye Care technology for patients, Mehta Eye Clinic has always believed in investing in the best. The Clinic has recently introduced LenSx® -the first of its kind, completely bladeless Laser Assisted Cataract Surgery in the city of Mumbai.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64151-mehta-eye-clinic-laser-cataract-surgery
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today congratulated trusted Edwards partner Dr. Albert Starr on receiving the 2015 Institut de France’s Grand Prix Scientifique in a Paris awards ceremony.
The Grand Prix is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. The Institut’s board awarded Starr the Grand Prix in recognition of research that led to the world’s first successful artificial mitral valve implant in 1960. In the last 55 years, millions of patients around the world have benefitted from the emergence of the field of heart valve replacement and the many technological advances that followed.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7536851-france-grand-prix-starr-edwards/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Many people equate a conversation about hospice as being told they must give up. However, more than 1 million people across the nation have learned just the opposite. They’ve been touched by the National Hospice and Palliative Care Organization’s “Moments of Life: Made Possible by Hospice” campaign since its launch on May 15, 2014. The campaign’s intent is to debunk this myth, and show that hospice focuses on compassionate, person-centered care, which enables special moments and memories at the end of life for patients and loved ones.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7154752-national-hospice-and-palliative-care-organization-nhpco-moments-of-life-psa/
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
